FDG-Labeled PET Scan in Planning Chemotherapy in Treating Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Status:
Completed
Trial end date:
2012-03-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well fludeoxyglucose F 18 (FDG)-labeled positron emission
tomography (PET) scan works in planning chemotherapy in treating patients with stage IIIB or
IV non-small cell lung cancer (NSCLC). Drugs used in chemotherapy, such as paclitaxel,
carboplatin, gemcitabine hydrochloride, and docetaxel, work in different ways to stop the
growth of tumor cells, either by killing the cells or by stopping them from dividing.
Diagnostic imaging procedures, such as FDG-labeled PET scan, may help in guiding chemotherapy
and allow doctors to plan better treatment